

## Dialysis Facility Scorecard Measure Specifications - December 2022

### Facility Scorecard Definitions:

**Network Measure:** CMS established measure for Networks.

**Network Goal:** CMS established goal for Networks.

**Facility Baseline:** Facility specific count or rate at baseline for each measure.

**Facility Specific Goal:** Facility specific goal calculated by the Network for each measure based on the CMS established goal.

**Facility Remeasurement:** Facility specific rate or count based on October 2022 data.

**Facility Percentile in the Network:** Percentile ranking for the facility for each measure based on October 2022 remeasurement data.

### Measure Specifications Table 1

Measure name	Numerator	Denominator	Attribution	Exclusion Criteria	Measure Time Periods <sup>1</sup>
Patients Identified with Depression and Receiving Treatment	Patients in the denominator with a Medicare outpatient claim for depression treatment by a mental health professional.	Patients with depression as identified by one of the checked variables in EQRS of: <ul style="list-style-type: none"> <li>• Screening for clinical depression is documented as being positive, and a follow-up plan is documented</li> <li>• Screening for clinical depression is documented as being positive, the facility possesses no documentation of a follow-up plan, and no reason is given</li> </ul>	Patients are attributed to the facility from which they received dialysis for at least 90 days during measure period	<ul style="list-style-type: none"> <li>• Patients less than 12 years of age</li> <li>• Patients treated at the dialysis facility for less than 90 days</li> <li>• Patients without positive depression screening reported</li> <li>• Patients with a positive depression screening that indicates the patient is not eligible for follow-up plan</li> <li>• Patients not enrolled in Medicare FFS</li> <li>• Patients without Medicare Part B coverage</li> <li>• Facilities with less than 11 eligible patients during the performance period</li> <li>• Facilities certified April 1 or later during performance year</li> </ul>	<p><u>Baseline:</u> January 1, 2020 – December 31, 2020</p> <p><u>Remeasurement:</u> January 1, 2022 – December 31, 2022</p>
Incident Patients Starting Home Dialysis	Count of Incident dialysis patients whose initial setting in EQRS is home during the performance period.  Incident is defined as an admission for one of the following:	None	Patients are attributed to the facility to whom the incident patient was admitted to	<ul style="list-style-type: none"> <li>• Transplant facilities</li> <li>• Patients discharged as acute</li> </ul>	<p><u>Baseline:</u> January 1, 2020 – December 31, 2020</p> <p><u>Remeasurement:</u> May 1, 2022 – April 30, 2023</p>

<sup>1</sup> Remeasurement is the full performance period. The Facility Scorecard Remeasurement reflects performance from the start of the remeasurement period to the most current data available.

Measure name	Numerator	Denominator	Attribution	Exclusion Criteria	Measure Time Periods <sup>1</sup>
	<ul style="list-style-type: none"> <li>New ESRD patient Restart</li> <li>Dialysis after transplant failed</li> </ul> <p>Due to CMS data requirements, if the count is 1-10, then the cell is blinded with "&lt; 11"</p>				
Prevalent Patients Transitioning to Home Dialysis	<p>Patient transitions to a home setting in EQRS during the performance period</p> <p>Due to CMS data requirements, if the count is 1-10, then the cell is blinded with "&lt; 11"</p>	None	Patients are attributed to the facility prior to the transition to home setting	<ul style="list-style-type: none"> <li>Patients whose only setting during the measurement period is home.</li> <li>Transplant facilities</li> </ul>	<p><u>Baseline:</u> January 1, 2020 – December 31, 2020</p> <p><u>Remeasurement:</u> May 1, 2022 – April 30, 2023</p>
Patients Added to the Transplant Waitlist	<p>Patients added to a kidney transplant waiting list within the performance period</p> <p>Due to CMS data requirements, if the count is 1-10, then the cell is blinded with "&lt; 11"</p>	None	Patients are attributed to the facility the patient was admitted to immediately prior to being added to a kidney transplant waiting list	<ul style="list-style-type: none"> <li>Transplant facilities</li> </ul>	<p><u>Baseline:</u> January 1, 2020 – December 31, 2020</p> <p><u>Remeasurement:</u> May 1, 2022 – April 30, 2023</p>
Patients Receiving a Kidney Transplant	<p>Patients who received a transplant within the performance period</p> <p>Due to CMS data requirements, if the count is 1-10, then the cell is blinded with "&lt; 11"</p>	None	Patients are attributed to the facility the patient was admitted to immediately prior to the transplant	<ul style="list-style-type: none"> <li>Transplant facilities</li> </ul>	<p><u>Baseline:</u> January 1, 2020 – December 31, 2020</p> <p><u>Remeasurement:</u> May 1, 2022 – April 30, 2023</p>
COVID-19 Hospitalizations per 100 Patient Months	Count of inpatient hospitalizations with a Medicare claim that includes a diagnosis of COVID-19 (ICD-10 U07.1)	The number of patient-months where patients are being treated in a dialysis facility during the performance period.	Patients are attributed to the facility where treatment was received as of the most current treatment record.	<ul style="list-style-type: none"> <li>The patient-month is excluded for patients not in enrolled in Medicare fee-for-service (FFS)</li> <li>Patients attributed to a transplant center</li> </ul>	<p><u>Baseline:</u> June 1, 2020 – April 30, 2021</p> <p><u>Remeasurement:</u> May 1, 2022 – April 30, 2023</p>

Measure name	Numerator	Denominator	Attribution	Exclusion Criteria	Measure Time Periods <sup>1</sup>
COVID-19 Patient Vaccinations – Initial or Completed Series	Denominator patients that have received a COVID-19 vaccination administration as reported in NHSN	Number of patients receiving dialysis care from this facility as reported to NHSN	Patients are attributed to their point prevalent dialysis facility	<ul style="list-style-type: none"> <li>Patients with a medical contraindication to COVID-19 vaccine</li> </ul>	<u>Baseline:</u> None <u>Remeasurement:</u> Most recent NHSN data
COVID-19 Patient Vaccination Booster	Denominator patients that have received a booster dose of COVID-19 vaccine as reported in NHSN	Total number of patients who have received any completed COVID-19 vaccination series	Patients are attributed to their point prevalent dialysis facility	<ul style="list-style-type: none"> <li>Patients with a medical contraindication to COVID-19 vaccine</li> </ul>	<u>Baseline:</u> None <u>Remeasurement:</u> Most recent NHSN data
COVID-19 Healthcare Personnel (HCP) Vaccinations – Initial or Completed Series	Denominator HCP that have received a COVID-19 vaccination administration as reported in NHSN	Number of all HCP that were eligible to have worked at this healthcare facility for at least one day during the week of data collection as reported to NHSN	HCP are attributed to the facility where they are work.	<ul style="list-style-type: none"> <li>HCP with a medical contraindication to COVID-19 vaccine</li> </ul>	<u>Baseline:</u> None <u>Remeasurement:</u> Most recent NHSN data
COVID-19 Healthcare Personnel (HCP) Vaccination Booster	Denominator HCP that have received a booster dose of COVID-19 vaccine as reported in NHSN	Total number of HCP who have received any completed COVID-19 vaccination series	HCP are attributed to the facility where they are work.	<ul style="list-style-type: none"> <li>HCP with a medical contraindication to COVID-19 vaccine</li> </ul>	<u>Baseline:</u> None <u>Remeasurement:</u> Most recent NHSN data
Influenza Patient Vaccination	Denominator patients with an influenza vaccination administration date from August 2022 through latest available record in EQRS	Patients on dialysis as of the end of the performance period	Patients are attributed to their dialysis facility as of the end of the measurement period	<ul style="list-style-type: none"> <li>Patients not receiving dialysis as of end of measurement period.</li> <li>Patients meeting following criteria will be excluded unless they have an influenza administration date of August 2022 or later reported in EQRS:               <ul style="list-style-type: none"> <li>Patients with a documented allergic or adverse reaction or other medical reason</li> <li>Patients that decline for religious or philosophical reasons.</li> </ul> </li> </ul>	<u>Baseline:</u> None <u>Remeasurement:</u> Most recent EQRS data

Measure name	Numerator	Denominator	Attribution	Exclusion Criteria	Measure Time Periods <sup>1</sup>
Patients receiving pneumococcal conjugate vaccine (PCV) 13	Number of dialysis patients with a PCV13 vaccination administration date reported in EQRS by the end of the performance period	Patients on dialysis as of the end of the performance period	Patients are attributed to their dialysis facility at the end of the performance period	<ul style="list-style-type: none"> <li>• Patients of not receiving dialysis as of end of measurement period.</li> <li>• Patients meeting following criteria will be excluded unless they have a PCV13 administration date reported in EQRS:               <ul style="list-style-type: none"> <li>○ Patients with a documented allergic or adverse reaction or other medical reason</li> <li>○ Patients that decline for religious or philosophical reasons.</li> <li>○ Patients with PCV15 or PCV20 vaccination reported in EQRS</li> <li>○ Patients with Unknown vaccination and date of January 1, 2022 or later reported in EQRS.</li> </ul> </li> </ul>	<p><u>Baseline:</u> Records in EQRS indicating PCV vaccination received in 2020 or earlier</p> <p><u>Remeasurement</u> Records in EQRS indicating PCV vaccination received in 2023 or earlier as of April 2023</p>
Patients Receiving Pneumococcal Polysaccharide Vaccine (PPSV23) - Initial	Denominator patients with a PPSV23 vaccination administration date reported in EQRS	Patients, age 2 years or older, on dialysis as of end of the performance period	Patients are attributed to their dialysis facility at the end of the performance period	<ul style="list-style-type: none"> <li>• Patients of not receiving dialysis as of end of measurement period.</li> <li>• Patients meeting following criteria will be excluded unless they have a PPSV23 administration date reported in EQRS:               <ul style="list-style-type: none"> <li>○ Patients with a documented allergic or adverse reaction or other medical reason</li> <li>○ Patients that decline for religious or philosophical reasons.</li> <li>○ Patients with PCV20 vaccination reported in EQRS</li> <li>○ Patients with Unknown vaccination and date of January 1, 2022, or later reported in EQRS.</li> <li>○ Patients younger than 2 years</li> </ul> </li> </ul>	<p><u>Baseline:</u> None</p> <p><u>Remeasurement:</u> Most recent EQRS data</p>

Measure name	Numerator	Denominator	Attribution	Exclusion Criteria	Measure Time Periods <sup>1</sup>
Patients Receiving a Pneumococcal Polysaccharide Vaccine (PPSV23)-Booster	Denominator patients that have PPSV23 booster vaccination administration date reported in EQRS	Patients on dialysis at the end of the performance period and have received an initial PPSV23 vaccination at least 5 years previously and prior to age 65	Patients are attributed to their dialysis facility at the end of the performance period	<ul style="list-style-type: none"> <li>• Patients of not receiving dialysis as of end of measurement period.</li> <li>• Patients meeting following criteria will be excluded unless they have a PPSV23 administration date reported in EQRS:               <ul style="list-style-type: none"> <li>○ Patients with a documented allergic or adverse reaction or other medical reason</li> <li>○ Patients that decline for religious or philosophical reasons.</li> <li>○ Patients with a PCV15 or PCV20 vaccination reported in EQRS</li> <li>○ Patients with Unknown vaccination and date of January 1, 2022, or later reported in EQRS.</li> <li>○ Patients who have not received an initial PPSV23 vaccination</li> <li>○ Patients who received an initial PPSV23 vaccination within the previous five years</li> <li>○ Patients aged 65 or older and received a PPSV23 vaccination</li> </ul> </li> </ul>	<p><u>Baseline:</u> Any PPSV23 in EQRS indicating 2020 or earlier as year received that is 5 or more years after initial</p> <p><u>Remeasurement:</u> Any PPSV 23 in EQRS indicating 2023 or earlier as year received that is 5 or more years after initial</p>
Patients Receiving Pneumococcal Polysaccharide Vaccine (PPSV23) - Age 65 or Older	Denominator patients with a PPSV23 vaccination administration date reported in EQRS	Patients on dialysis at the end of the performance period age 65 or older	Patients are attributed to their dialysis facility at the end of the measurement period	<ul style="list-style-type: none"> <li>• Patients of not receiving dialysis as of end of measurement period.</li> <li>• Patients meeting following criteria will be excluded unless they have a PPSV23 administration date reported in EQRS:               <ul style="list-style-type: none"> <li>○ Patients with a documented allergic or adverse reaction or other medical reason</li> <li>○ Patients that decline for religious or philosophical reasons.</li> <li>○ Patients with a PCV15 or PCV20 vaccination reported in EQRS</li> <li>○ Patients with Unknown vaccination and date of January 1, 2022, or later reported in EQRS.</li> <li>○ Patients who have not received an initial PPSV23 vaccination</li> <li>○ Patients who received an initial PPSV23 vaccination within the previous five years</li> <li>○ Patients younger than age 65</li> </ul> </li> </ul>	<p><u>Baseline:</u> None</p> <p><u>Remeasurement:</u> Most recent EQRS data</p>

Measure name	Numerator	Denominator	Attribution	Exclusion Criteria	Measure Time Periods <sup>1</sup>
ESRD-Related Hospitalizations per 100 Patient Months	Count of ESRD-related inpatient hospital admissions during the performance period with a Medicare claim for primary diagnosis from Appendix A.	The number of patient-months where patients are being treated in a dialysis facility during the performance period.	Patients are attributed to the facility where treatment was received as of the most current treatment record.	The patient-month is excluded for <ul style="list-style-type: none"> <li>Patients not in enrolled in Medicare fee-for-service (FFS)</li> <li>Patients attributed to a transplant center</li> </ul>	<u>Baseline:</u> June 1, 2020 – April 30, 2021  <u>Remeasurement:</u> May 1, 2022 – April 30, 2023
Hospital 30-Day Unplanned Readmissions	Count of index admissions with at least one ESRD-related unplanned readmission with the following: <ul style="list-style-type: none"> <li>a Medicare claim with a primary diagnosis from Appendix A.</li> <li>an admission admit within 30 days of discharge from the index admission,</li> <li>Not a planned visit as defined by the CMS Planned Readmission Algorithm</li> </ul>	ESRD-related inpatient admission (index admission) with the following: <ul style="list-style-type: none"> <li>Discharge during the performance period</li> <li>Has a primary diagnosis from Appendix A</li> <li>Patient is discharged alive.</li> </ul> Note that, as with other CMS readmission measures, the denominator is discharges, not patients, and each patient can contribute more than one discharge.	Patients are attributed to the facility where treatment was received as of the most current treatment record.	Discharges are excluded for <ul style="list-style-type: none"> <li>Patients not in enrolled in Medicare fee-for-service (FFS)</li> <li>Patients attributed to a transplant center</li> </ul>	<u>Baseline:</u> Index Admission Discharge Date: June 1, 2020 – April 30, 2021  Readmission Admit Date: June 1, 2020 - May 31, 2021  <u>Remeasurement:</u> Index Admission Discharge Date: June 1, 2022 – April 30, 2023  Readmission Admit Date: June 1, 2022 - May 31, 2023
Outpatient Emergency Department Visits per 100 Patient Months	Count of ESRD-related emergency room treat-and-release visits during the performance period with a Medicare claim with a primary diagnosis from Appendix A.	The number of patient-months where patients are being treated in a dialysis facility during the performance period.	Patients are attributed to the facility where treatment was received as of the most current treatment record.	The patient-month is excluded for <ul style="list-style-type: none"> <li>Patients not in enrolled in Medicare fee-for-service (FFS)</li> <li>Patients attributed to a transplant center</li> </ul>	<u>Baseline:</u> June 1, 2020 – April 30, 2021  <u>Remeasurement:</u> May 1, 2022 – April 30, 2023
Facility Engages Patients & Families in QAPI	Yes/No based on if the facility has engaged patients and/or family member(s) in the QAPI program and has attested to such with the Network during the baseline or remeasurement period.	N/A	N/A	N/A	<u>Baseline:</u> June 1, 2020 – April 30, 2021  <u>Remeasurement:</u> May 1, 2021 – April 30, 2023

Measure name	Numerator	Denominator	Attribution	Exclusion Criteria	Measure Time Periods <sup>1</sup>
Facility Engages Patients & Families in Life Planning	Yes/No based on if the facility has engaged patients and/or family member(s) in Life Planning and has attested to such with the Network during the baseline or remeasurement period.	N/A	N/A	N/A	<u>Baseline:</u> June 1, 2020 – April 30, 2021  <u>Remeasurement:</u> May 1, 2021 – April 30, 2023
Facility Established a Patient & Family Peer Mentoring Program	Yes/No based on if the facility has established a patient peer mentoring program and has attested to such with the Network during the baseline or remeasurement period.	N/A	N/A	N/A	<u>Baseline:</u> June 1, 2020 – April 30, 2021  <u>Remeasurement:</u> May 1, 2021 – April 30, 2023
Data Quality – Patient Admissions Submitted On Time	Number of admission records in EQRS with an admission record created date within 5 business days of the admission date	Admission records for most recent 12 month period	Patients are attributed to facility admitting patient	<ul style="list-style-type: none"> <li>• Transplant facilities</li> <li>• Patients discharged as Acute</li> </ul>	<u>Baseline:</u> January 1, 2020 – December 31, 2020  <u>Remeasurement:</u> Rolling 12 month period using most recent EQRS data
Data Quality – 2728 Forms Submitted On Time	Number of Initial Dialysis 2728 forms submitted in EQRS with a submitted date within 45 days of the Dialysis at Facility Start Date	Number of Initial Dialysis 2728 forms submitted for most recent 12 month period	Patients are attributed to facility submitting form	<ul style="list-style-type: none"> <li>• Facility type of Transplant</li> <li>• Patients discharged as Acute</li> <li>• Patients discharged as Recover Function where discharge date is before form submission date</li> </ul>	<u>Baseline:</u> January 1, 2020 – December 31, 2020  <u>Remeasurement:</u> Rolling 12 month period using most recent EQRS data
Data Quality – 2746 Forms Submitted On Time	Number of 2746 forms submitted in EQRS with a submitted date within 14 days of the death date	Number of 2746 forms submitted for most recent 12 month period	Patients are attributed to facility submitting form	<ul style="list-style-type: none"> <li>• Facility type of Transplant</li> <li>• Patients discharged as Acute</li> <li>• Patients discharged as Recover Function where discharge date is before form submission date</li> </ul>	<u>Baseline:</u> January 1, 2020 – December 31, 2020  <u>Remeasurement:</u> Rolling 12 month period using most recent EQRS data

## Appendix A: List of Priority Diagnosis Categories

- A419 Sepsis, unspecified organism
- E875 Hyperkalemia
- E8770 Fluid overload unspecified
- I214 Non-ST elevation (N STEMI) myocardial infarction
- I120 Hypertensive chronic kidney disease stage 5 or end stage renal disease
- T82868A Thrombosis due to vascular prosthetic devices, implants and grafts, initial encounter
- T82868D Thrombosis due to vascular prosthetic devices, implants and grafts, subsequent encounter
- T82868S Thrombosis due to vascular prosthetic devices, implants and grafts, sequela
- I161 Hypertensive Emergency
- T8571XA Infection and inflammatory reaction due to peritoneal dialysis catheter, initial encounter
- T8571XD Infection and inflammatory reaction due to peritoneal dialysis catheter, subsequent encounter
- T8571XS Infection and inflammatory reaction due to peritoneal dialysis catheter, sequela
- T80211A Bloodstream infection due to central venous catheter, initial encounter
- T80211D Bloodstream infection due to central venous catheter, subsequent encounter
- T80211S Bloodstream infection due to central venous catheter, sequela
- T82838A Hemorrhage due to vascular prosthetic devices, implants and grafts, initial encounter
- T82838D Hemorrhage due to vascular prosthetic devices, implants and grafts, subsequent encounter
- T82838S Hemorrhage due to vascular prosthetic devices, implants and grafts, sequela
- E8779 Other fluid overload
- I2510 Atherosclerosis heart disease of native coronary artery without angina pectoris
- J810 Acute pulmonary edema
- A4101 Sepsis due to Methicillin Susceptible Staphylococcus aureus
- A4102 Sepsis due to Methicillin Resistant Staphylococcus aureus
- T82858A Stenosis of other vascular prosthetic devices, implants and grafts, initial encounter
- T82858D Stenosis of other vascular prosthetic devices, implants and grafts, subsequent encounter
- T82858S Stenosis of other vascular prosthetic devices, implants and grafts, sequela
- R079 Chest pain, unspecified
- D649 Anemia unspecified
- E1110 DM Type 2 with ketoacidosis without coma
- A4181 Sepsis due to Enterococcus
- E1122 Diabetes type 2 with diabetic chronic kidney disease
- I169 Hypertensive Crisis, Unspecified
- E871 Hypo-osmolality and hyponatremia
- E876 Hypokalemia
- E162 Hypoglycemia, unspecified
- A4150 Gram-negative sepsis, unspecified